Wire · opportunities
Medtronic expands cSDH treatment options with FDA clearance of Aristotle® Mini Guidewire
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 November 2026 · Fusion42 review
Medtronic received FDA clearance for the Aristotle® Mini Guidewire, expanding treatment options for chronic subdural hematoma (cSDH) by enabling better access to small, distal vessels during embolization procedures. This launch complements Medtronic's existing neurovascular portfolio, including the recently approved Onyx™ 12 Liquid Embolic System.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 9 Nov 2026 and 15 Nov 2026.
◆ ◆ The Wire takeaway
You now have a smaller, more flexible guidewire option to deliver therapies in tricky neurovascular cases. This clearance opens a clear path to compete in growing cSDH treatments by supporting advanced vessel access.
◆ Coverage
3 sources · first reported 9 Nov 2026 · latest 15 Nov 2026
◆ Related on Wire
◆ Topics